On this page
Eloralintide Quick Reference (10 mg Vial)
- Vial contents
- 10 mg Eloralintide
- Final volume
- 1 mL
- Concentration
- 10 mg/mL
- One U-100 unit
- 100 mcg in 0.01 mL
Eloralintide Dosage Chart
Dosage & Reconstitution Guide
Phase 2 Fixed-Dose Arms Using a 10 mg/mL Worked Preparation
Phase 2 Fixed-Dose Arms Using a 10 mg/mL Worked Preparation
| Research Period | Amount per Administration | U-100 Units (mL) |
|---|---|---|
| 48 weeks | 1 mg | 10 units (0.10 mL) |
| 48 weeks | 3 mg | 30 units (0.30 mL) |
| 48 weeks | 6 mg | 60 units (0.60 mL) |
| 48 weeks | 9 mg | 90 units (0.90 mL) |
Frequency: Once weekly in the cited phase 2 trial.[1][4]
Research reference only: The dose amounts and 48-week period come from a human phase 2 trial. Rows represent separate fixed-dose arms, not a progression. The U-100 conversions depend on the stated 1.0 mL worked preparation, which was not established by the trial publication.
Reconstitution Steps
- Clean the vial stopper and diluent stopper with alcohol; allow both to dry.
- Draw exactly 1.0 mL of bacteriostatic water with a new sterile syringe, then inject it slowly down the inside wall of the vial.
- Gently swirl or roll until dissolved. Do not shake.
- Label the vial with the compound, concentration, and reconstitution date. Refrigerate at 2–8 °C (36–46 °F) and protect from light.
Storage note: No compound-specific post-reconstitution stability or discard period has been established for this worked research-vial preparation. Follow the lot-specific product documentation for any shorter limit.
Supplies Needed
Each row is a separate 48-week fixed-dose calculation. Do not add the rows together.
- Peptide Vials (Eloralintide, 10 mg each):
- 48 weeks at 1 mg/week: 5 vials
- 48 weeks at 3 mg/week: 15 vials
- 48 weeks at 6 mg/week: 29 vials
- 48 weeks at 9 mg/week: 44 vials
- Insulin Syringes (U-100):
- 48 weekly administrations: 48 syringes
- Bacteriostatic Water (10 mL bottles):
- 5-vial calculation: 5 mL
- 15-vial calculation: 15 mL
- 29-vial calculation: 29 mL
- 44-vial calculation: 44 mL
- Alcohol Swabs:
- 48 weekly administrations at 2 swabs each: 96 swabs
Sharps safety: Place used needles and syringes immediately in an approved sharps container.
Peptide Reconstitution Simulator
Practice preparing this vial with the verified strength and final volume from this protocol.
Eloralintide Vial and Research Context
- Reconstitute: Add 1.0 mL bacteriostatic water for a worked concentration of 10 mg/mL.
- Vial contents: 10 mg Eloralintide.
- U-100 conversion: 1 unit = 0.01 mL = 100 mcg.
- Storage: Refrigerate at 2–8 °C and protect from light.
Eloralintide is an investigational amylin-receptor agonist. The trial doses are published human-study amounts; the 1.0 mL vial preparation is a worked calculation and is not a claim of formulation equivalence.[1][2][3]
Eloralintide Dose-Finding Research
Eloralintide is an investigational, selective amylin-receptor agonist. A phase 2 trial evaluated once-weekly fixed doses of 1, 3, 6, and 9 mg, along with escalation arms, for 48 weeks.[1][4] An earlier proof-of-concept study evaluated once-weekly subcutaneous administration over 12 weeks, while a discovery report described single 4 mg and 12 mg doses.[2][3]
These studies support the charted amounts and weekly frequency. They do not disclose or validate the 1.0 mL research-vial preparation used for U-100 calculations on this page.
10 mg Vial Calculation Notes
- 10 mg divided by 1.0 mL equals 10 mg/mL.
- One U-100 unit equals 0.01 mL or 100 mcg.
- 1, 3, 6, and 9 mg equal 10, 30, 60, and 90 units, respectively.
- Each 48-week vial count is rounded up to the next whole 10 mg vial.
Amylin Receptor Research Context
Investigational Status and Evidence Limits
Eloralintide remains investigational. Phase 1 and phase 2 results must be interpreted with their enrolled populations, dose-escalation rules, adverse-event monitoring, and study formulations.[1][2][4][5] A research vial requires its own identity, purity, sterility, stability, and clinical-pharmacology evidence.[11]
References
- 1Wharton et al., 2025, PMID 41207310 – Phase 2 randomized trial of once-weekly fixed and dose-escalation eloralintide regimens over 48 weeks in adults with obesity or overweight.
- 2Frias et al., 2026, PMID 41559929 – Phase 1 proof-of-concept study of once-weekly subcutaneous eloralintide over 12 weeks.
- 3Mather et al., 2025, PMID 41109426 – Discovery and clinical proof-of-concept report including single 4 mg and 12 mg eloralintide doses.
- 4ClinicalTrials.gov NCT06230523 – Registry record for the phase 2 eloralintide obesity study.
- 5ClinicalTrials.gov NCT05295940 – Registry record for an early eloralintide clinical study.
- 6Hay et al., 2015, PMID 25917562 – Review of amylin pharmacology and receptor biology.
- 7Lutz, 2012, PMID 23166332 – Review of amylin physiology and energy-balance mechanisms.
- 8Boyle et al., 2022, PMID 35066542 – Review of amylin analogs and emerging obesity pharmacotherapy.
- 9Jorsal et al., 2016, PMID 26812892 – Review of amylin and calcitonin-family receptors in metabolic disease.
- 10Mietlicki-Baase and Hayes, 2014, PMID 24262967 – Review of central amylin signaling and energy balance.
- 11U.S. FDA, Clinical Pharmacology Considerations for Peptide Drug Products – Regulatory guidance on evidence expected during peptide drug development.